This presentation by Michael Sand, United States, was recorded on 20 January 2025 at the ECNP Roadmap Meeting on Precision Psychiatry in Frankfurt, Germany.
This talk presents the AMP Schizophrenia Initiative, an international collaboration to develop biomarkers for schizophrenia drug development. The initiative includes an observational study and a proof-of-principle trial, involving public and private sector partnerships. The observational study tests biomarkers in a high-risk population for psychosis, while the trial evaluates their clinical utility. Assessments include clinical tasks, cognitive tasks, MRI, EEG, serum biomarkers, and digital assessments. Nearly 2,000 high-risk individuals and 640 healthy controls have been recruited. Preliminary results show promising findings, and data will be made available to the research community.
Views and opinions expressed in these videos are those of the presenters and do not necessarily reflect the official position of ECNP. The content of these videos should not be used in any way as the basis for treatment decisions.
